Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
Status:
Not yet recruiting
Trial end date:
2027-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the efficacy of sugemalimab consolidation therapy
versus placebo in patients with LS-SCLC who had not progressed following Concurrent or
Sequential Chemoradiotherapy.